EN DE
Watch Cambridge Nutritional Sciences plc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cambridge Nutritional Sciences plc (CNSL) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Cambridge Nutritional Sciences plc stock £0.02, price £0.02, upside +4.5%, quality 48 out of 100. Rating: fairly valued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB

CN Cambridge Nutritional Sciences plc logo Thin data Nov 5, 2026

Cambridge Nutritional Sciences plc

CNSL · LSE
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Fair value £0.0162 · Fairly valued
Quality 48/100
Revenue last quarter 26% below a year ago.
Weak Growth (revenue 5y +0.5 %/yr in GBP)
Loss-making · -83.5% net margin (TTM)
Negative free cash flow
Trails peers (3/9)
Narrow moat 10/100 · thin data
Thin data
Watch Cambridge Nutritional Sciences plc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£0.5800 £0.0140 Fair Value £0.0162 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range £0.0140 – £0.5800 · fair‑value band £0.0146 – £0.0162 · the £0.0155 price screens below the £0.0162 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.

Follow Cambridge Nutritional Sciences in your weekly email

Every Wednesday you see whether Cambridge Nutritional Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cambridge Nutritional Sciences plc, together with its subsidiaries, develops, manufactures, and distributes medical diagnostics products for the food sensitivity testing market.

Show moreShow less

The company is involved in the research, development, and production of kits for detection of immune reactions to food under the FoodPrint brand. It also provides clinical analysis to the general public, clinics, and health professionals; and supplies Food Detective, a food sensitivity test.

In addition, the company offers My Health Tracker, a health app for tracking symptoms, accessing FoodPrint results, and managing gut health; and CNS Lab, which provides laboratory services for food sensitivity.

It serves the government, private hospitals and clinics, reference laboratories, nutritionists, naturopaths, consumers, and functional medicine healthcare practitioners in the United Kingdom, rest of Europe, North America, South/Central America, India, rest of Asia and the Far East, Africa, and the Middle East.

The company was formerly known as Omega Diagnostics Group PLC and changed its name to Cambridge Nutritional Sciences plc in September 2023. Cambridge Nutritional Sciences plc is based in London, the United Kingdom.

Stock analysis

Cambridge Nutritional Sciences plc (CNSL) currently trades at £0.0155, while our model-based Fair Value estimate is £0.0162, so the stock looks roughly fairly valued today (gap 4.3%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: £0.0146 (bear) to £0.0162 (bull), the price of £0.0155 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Cambridge Nutritional Sciences plc reported revenue of £7.0M in FY2026 versus £8.5M in FY2022, a compound −4.9%/yr. Reported net income was −£5.8M in FY2026.

Key figures

Market cap £3.7M Micro · P/S ratio 0.53 · EPS (TTM) £−0.0200 · Net margin −83.5% · Return on equity −68.2% · Return on assets (EBIT) −9.0% (5-year average) · Operating margin −29.3% · Revenue (TTM) £7.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 42% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at 5%, CNSL screens cheaper than that median.

Fair Value models

Bear £0.0146 Fair Value £0.0162 Bull £0.0162
Price £0.0155 · Upside +4.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) £0.0100 £0.0200 £0.0200 53
All 1 models by family
Asset-Based
NCAV (Graham) £0.0100 £0.0200 £0.0200 53

Open the full fair value analysis →

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 34
How much profit the company makes from its sales and capital
Quality Growth 33
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 18
How calm the share price moves, does not count
Price momentum 12
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 8
Distance to the 52-week high, does not count
New shares 78
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−16.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.5%
Start year 2021 (pandemic). Over 10 years: −5.8% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−7.2% (2021) → −15.0% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch CNSL, get fair value alerts →

Compare Cambridge Nutritional Sciences plc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 48 · Bottom 25%
Fair Value upside +4.5% · Above median
Profitability
Return on assets −78.2% · Bottom 25%
Net margin (12 months) −83.5% · Bottom 25%
Operating margin (12 months) −29.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −25.8% · Bottom 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 0.65× · Cheapest 25%
P/S (12 months) 0.53× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)39 · sector 25
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 30
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.38 $131.27 +45% vs CNSL
EssilorLuxottica Société anonyme EL €193.80 €196.22 +1% vs CNSL
Intuitive Surgical, Inc ISRG $452.80 $353.90 −22% vs CNSL
Medline Inc MDLN $39.64 $28.59 −28% vs CNSL
Alcon Inc ALC CHF 61.30 CHF 34.06 −44% vs CNSL
Becton, Dickinson and Company BDX $211.88 $97.80 −54% vs CNSL
Straumann Holding STMN CHF 104.50 CHF 45.50 −56% vs CNSL
West Pharmaceutical Services, Inc WST $399.81 $139.22 −65% vs CNSL
Sartorius Stedim Biotech S.A DIM €225.80 €54.82 −76% vs CNSL
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs CNSL

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cambridge Nutritional Sciences plc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cambridge Nutritional Sciences plc Fair Value". https://www.fairvalue-calculator.com/stock/CNSL

Frequently asked questions

Is Cambridge Nutritional Sciences plc (CNSL) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of £0.0162 versus a price of £0.0155, about +5% upside (fairly valued).
What is the fair value of CNSL?
Our model-based fair value for Cambridge Nutritional Sciences plc is £0.0162 (as of Nov 5, 2026), built from audited fundamentals. The current price: £0.0155.
What is the quality score of CNSL?
Cambridge Nutritional Sciences plc has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cambridge Nutritional Sciences plc (CNSL)?
Our model-based price target is the fair value of £0.0162 (as of Nov 5, 2026) from 1 valuation models. Cautious scenario £0.0146, optimistic scenario £0.0162. It is a calculation from audited fundamentals, not an analyst target.
What is the Cambridge Nutritional Sciences plc stock forecast for 2026?
Our models put fair value at £0.0162, about +5% upside versus a price of £0.0155 (fairly valued). Cautious scenario £0.0146, optimistic scenario £0.0162. The calculation is refreshed regularly with new filings.
What is the revenue of Cambridge Nutritional Sciences plc (CNSL)?
Cambridge Nutritional Sciences plc reported trailing-twelve-month revenue of about £7.0M (latest available figure, as of Nov 5, 2026).
What is the intrinsic value of Cambridge Nutritional Sciences plc (CNSL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cambridge Nutritional Sciences plc it is £0.0162 per share (as of Nov 5, 2026), against a price of £0.0155. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Cambridge Nutritional Sciences plc stock overvalued or undervalued in 2026?
As of Nov 5, 2026, CNSL trades below its calculated fair value: price £0.0155, fair value £0.0162, a gap of about +5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CNSL?
No. The price is what the market pays today (£0.0155); the fair value is what the company's own numbers justify (£0.0162). For Cambridge Nutritional Sciences plc the two are £0.0007 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cambridge Nutritional Sciences plc worth?
The market values Cambridge Nutritional Sciences plc at about £3.7M (market capitalisation, as of Nov 5, 2026). Per share that is £0.0155; our models calculate a fair value of £0.0162 per share.
What do the bullish and bearish scenarios say about CNSL?
Our models span a range for Cambridge Nutritional Sciences plc: cautious scenario £0.0146, base £0.0162, optimistic £0.0162 per share (as of Nov 5, 2026, price £0.0155). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cambridge Nutritional Sciences plc (CNSL)?
Balance-sheet figures for Cambridge Nutritional Sciences plc (as of Nov 5, 2026): return on equity −68.2%. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is CNSL from its 52-week high?
Cambridge Nutritional Sciences plc trades at £0.0155, about 42% below its 52-week high of £0.0265 and 11% above the low of £0.0140 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of £0.0162 is for.
Which stocks are comparable to Cambridge Nutritional Sciences plc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cambridge Nutritional Sciences plc stock attractive at the current price?
The data as of Nov 5, 2026: price £0.0155, calculated fair value £0.0162 (+5%), Quality Score 48/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CNSL calculated?
We run Cambridge Nutritional Sciences plc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of £0.0162 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Cambridge Nutritional Sciences plc currently trades 4% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cambridge Nutritional Sciences plc (CNSL)?
The closing price on Nov 6, 2026 was £0.0155. Our model-based fair value is £0.0162, about +5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cambridge Nutritional Sciences plc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (£0.0146 to £0.0162), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Cambridge Nutritional Sciences plc

How large is the market capitalisation of Cambridge Nutritional Sciences plc (CNSL)?
The market capitalisation of Cambridge Nutritional Sciences plc is £3.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cambridge Nutritional Sciences plc (CNSL)?
The price-to-sales ratio of Cambridge Nutritional Sciences plc is 0.53 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cambridge Nutritional Sciences plc (CNSL)?
Earnings per share at Cambridge Nutritional Sciences plc are £−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cambridge Nutritional Sciences plc (CNSL)?
The net margin of Cambridge Nutritional Sciences plc is −83.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cambridge Nutritional Sciences plc (CNSL)?
The return on equity (ROE) of Cambridge Nutritional Sciences plc is −68.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cambridge Nutritional Sciences plc (CNSL)?
On an EBIT basis the return on assets of Cambridge Nutritional Sciences plc is −9.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cambridge Nutritional Sciences plc (CNSL)?
The operating margin of Cambridge Nutritional Sciences plc is −29.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cambridge Nutritional Sciences plc (CNSL)?
Revenue at Cambridge Nutritional Sciences plc is growing −25.8% versus a year earlier (3y avg −2.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cambridge Nutritional Sciences plc (CNSL)?
Earnings per share at Cambridge Nutritional Sciences plc are growing +376% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Cambridge Nutritional Sciences plc (CNSL) generate?
The free cash flow of Cambridge Nutritional Sciences plc is −£1.4M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Cambridge Nutritional Sciences plc (CNSL) hold?
Cambridge Nutritional Sciences plc holds more cash than debt, £2.5M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Cambridge Nutritional Sciences plc in the live analysis

One click puts Cambridge Nutritional Sciences plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.